By January 2022, 12 billion COVID-19 vaccine doses had been manufactured and, to date, roughly 20 vaccines have received either full approval or emergency use authorization in countries around the world. In places such as Europe and the U.S., most of the people who want vaccinations have gotten their jabs. And the vaccines continue to show efficacy, with the latest CDC data showing consistently less risk for testing positive for COVID-19 or dying from the infection for those who are vaccinated and boostered. Yet the development of new COVID-19 vaccines remains surprisingly robust, with BioWorld tracking 258, the majority of which are in preclinical development.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Ampio, Dragon Boat, Hansa, Moleculin, Nrx, Otsuka, Tvardi, Vertex, Zambon.
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Alzecure, Arev, Celsion, Codiak, Gilead, ICER, Immune-Onc, Janssen, Legend, Pfizer, Sanofi, Terran, Vallon.
Astrazeneca plc led the handful of firms rolling out COVID-19-related news, as the company said detailed results from the Provent phase III pre-exposure prophylaxis (prevention) trial with Evusheld (tixagevimab and cilgavimab), were published in the New England Journal of Medicine, the “culmination of about 19 months of pretty intensive work,” said Mark Esser, vice president of microbial sciences.
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Aim Immunotech, Biogen, Blue Water Vaccines, Humanigen, Immvira, Roche, Samsung Bioepis, Selva, Sihuan Pharma, Tonix, Xortx, Xuansheng Pharma.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Arcturus, Bavarian Nordic, Clover, Fibrogen, Navidea, Otonomy, Snipr, Trevena, Ultragenyx, Windtree.
Arcturus Therapeutics Holdings Inc. reported that ARCT-154, its self-amplifying mRNA COVID-19 vaccine, showed efficacy of 55% against infection and 95% efficacy against severe disease, meeting the primary and key secondary endpoints of the ongoing phase I/II/III trial. While the company’s stock (NASDAQ:ARCT) regained much of its initial 25% drop to close the day, investors continue to await further data to determine where Arcturus’ vaccine will fit in with available COVID-19 vaccines.